Starling Oncology jumped 28% to US$6.41 after its Q2 release, a sharp repricing for a stock that had already logged strong double digit gains over the past quarter. The headline is not earnings per share; the swing factor is cash and profitability.

Starling Oncology booked its second profitable quarter on an adjusted EBITDA basis and reported positive free cash flow alongside US$41.1m of cash and a fresh term loan that pushed major debt maturities out to 2031. The market moved on the day. The real debate now is how durable that profit and cash profile looks over the next few years.

Is Starling Oncology now a genuine bargain on 1.1x P/S, or is the market pricing in more balance sheet and profitability risk than the rally suggests? See how the stock screens against peers in our valuation analysis for Starling Oncology.

Q2 2026 Earnings Summary

• Revenue (Q2 2026 vs. Q2 2025): US$161.3m vs. US$119.8m (up 34.6%)
• Net Income/Loss (Q2 2026 vs. Q2 2025): loss of US$9.8m vs. loss of US$14.0m (narrowed loss)
• Basic EPS (Q2 2026 vs. Q2 2025): loss of US$0.10 per share vs. loss of US$0.15 per share (narrowed loss per share)
• Medical Loss Ratio (MLR, Q2 2026 vs. Q2 2025): 85.5% vs. 71% (higher medical cost ratio on capitated members)

Prefer clean charts over scrolling through pages of figures and footnotes? View Starling Oncology's full visual profile, including a clear breakdown of its balance sheet strength and debt position, in our company report for Starling Oncology.

Starling Oncology’s Bull Case Meets Key Profit Milestones

The bullish story around Starling Oncology has centred on a shift to higher visibility revenue, improving margins and eventual free cash flow strength. Q2 gives concrete progress against that script. Delegated capitation is moving from concept to scale, with three new contracts across Nevada, Oregon and California and about US$56m of incremental annualized capitation revenue cited. That directly supports the push toward recurring, value based oncology flows.

Pharmacy is doing exactly what the thesis called for. Specialty pharmacy now contributes US$98.6m of revenue and US$21.3m of gross profit with a higher margin than a year ago, which aligns with the idea of pharmacy as a growing profit pool. Most important for a rerating story, Starling Oncology has now reported a second quarter of positive adjusted EBITDA and positive free cash flow, while refinancing near term debt maturities. That is a clear milestone for a business once defined by funding risk.

Compare Starling Oncology’s profit milestones and cash improvements with how institutional analysts are calibrating their expectations. See the consensus price target analysis for Starling Oncology.

Starling Oncology Bear Case: Margin Fears Not Put To Rest

The key bearish claim is that Starling Oncology’s shift into delegated capitation and specialty pharmacy carries margin and balance sheet risk that could blunt the benefit of revenue scale. Q2 does not fully disprove that. Total capitated Medical Loss Ratio at 85.5% is at the high end of what management describes as a steady state range and well above the 71% level a year ago. That supports the concern that onboarding new lives can pressure margins and that profitability is fragile.

Patient services gross profit fell to US$2.1m from US$4.7m while pharmacy did the heavy lifting. That concentration keeps bears focused on reimbursement and high cost drug exposure. The refinancing and US$41.1m cash position reduce near term funding stress but do not remove it. Positive adjusted EBITDA of US$0.2m and modest full year EBITDA guidance leave limited room for execution slip on MLR or contract ramps.

Review whether Starling Oncology’s thin EBITDA cushion and refinancing truly address deeper structural fragilities. Expose our full risk analysis for Starling Oncology which shows 3 important warning signs.

Stay Ahead With Simply Wall St

If Starling Oncology’s rapid shift in profitability and cash generation has your attention, register for free with Simply Wall St and add it to a Watchlist to track the share price against fair value and watch how the thesis develops. After you take a position, use the Portfolio Command Center to cut through market noise and focus on the key updates that matter for your holdings. For a broader view on sentiment and different angles on Starling Oncology and similar stocks, tap into the Community and see how other investors are thinking. By spotting potential catalysts and risks early, you give yourself a better chance of staying ahead of the market.

Seeking Alternatives Beyond Starling Oncology?

New ideas can move fast when momentum builds and fresh stories are still under the radar for now. Scan these curated lists before the best entry points are gone, act now.

• Spot resilient businesses where balance sheets do the heavy lifting and cash strength supports the thesis by reviewing the list of solid balance sheet and fundamentals stocks (49 results).
• Hunt for powerful income ideas that could keep portfolios steady while markets keep flying around by using the curated 8 dividend fortresses.
• Target under followed opportunities with real quality filters already applied by scanning the hand picked 19 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.